Qnexa May Get Staged Launch After No Vote From Advisory Panel

Limited distribution could be a path to approval sooner, rather than later, for Vivus' obesity drug Qnexa following the Endocrinologic and Metabolic Drugs Advisory Committee's recommendation against approval July 15